Aberrant sialylation of serum IgA1 was associated with prognosis of patients with IgA nephropathy
Aberrant sialylation of serum IgA1 was associated with prognosis of patients with IgA nephropathy
复制标题
血清IgA1唾液酸化异常与IgA肾病患者预后相关
DOI：
10.1016/j.clim.2007.08.009
复制
发表时间：
2007-12-01
影响因子：
8.6
通讯作者：
Wang, Hai-Yan
中科院分区：
文献类型：
--
作者：
Ding, Jia-Xiang;Xu, Li-Xia;Wang, Hai-Yan
血清IgA_1糖基化异常被认为是IgA肾病的起始事件，参与了IgA肾病的发病过程。我们以前证明，异常糖基化的血清IgA 1与病理表型的IgAN肾病。本研究旨在探讨IgA 1唾液酸化异常是否影响IgA肾病患者的肾存活率。入选127例经活检证实的IgAN患者，并随访8年。选择79例健康人和75例非IgAN肾病患者作为对照。ELISA法测定血清IgA 1中α 2，6唾液酸（SA）。采用Kaplan-Meier法计算肾存活率。IgAN患者血清α 2，6 SA水平低于健康对照组（0. 05 ± 0. 05）。92 +/- 0.14 vs. 0.98 +/- 0.12，P=0.001）和非IgAN肾小球肾炎（0.92 +/- 0.14 vs. 1.00 +/- 0.18，n= 53，P=0.001）。低SA组IgAN患者与正常SA组患者在年龄、性别、高血压、血清肌酐和蛋白尿排泄方面无显著差异。低SA组肾累积存活率为53.3%，正常SA组为83.5%（P=0.0008）。IgAN患者血清IgA 1 α 2，6 SA水平越低，肾存活率越低。虽然低SA组患者eGFR评估的肾功能较差，但在非IgAN肾功能对照组的不同CKD分期中无显著差异（n=42，P=0.352）。血清IgAl α 2，6 SA水平与IgAN患者的预后有关，可作为IgAN患者预后不良的预测指标。(c)2007爱思唯尔公司All rights reserved.
Aberrant glycosylation of serum IgA1 was considered as an initial event and involvement in the pathogenesis of IgAN. We previously demonstrated that aberrant glycosylation of serum IgA1 was associated with pathologic phenotype of IgAN. The present study is to investigate if abnormal sialylation of IgA1 affects renal survival of IgAN. 127 patients with biopsy-proven IgAN were enrolled and followed up to 8 years. Seventy-nine healthy and 75 patients with non-IgAN renal diseases were selected as controls. Alpha 2, 6 sialic acid (SA) of serum IgAl was measured by sandwich-ELISA. Renal survival rate was estimated by Kaplan-Meier method. Alpha 2, 6 SA level in patients with IgAN was tower than that in healthy controls (0. 92 +/- 0.14 vs. 0.98 +/- 0.12, P=0.001) and non-IgAN glomerulonephritis (0.92 +/- 0.14 vs. 1.00 +/- 0.18, n= 53, P=0.001). Patients with IgAN in Low SA Group were no significant differences compared with patients in Normal SA Group in age, gender, hypertension, serum creatinine, and excretion of proteinuria. Renal cumulative survival rate was 53.3% in patients in Low SA Group and 83.5% in Normal SA Group (P=0.0008). The lower the alpha 2, 6 SA level of serum IgAl in patients with IgAN was, the worse their renal survival rate was. Although patients in Low SA Group had worse renal function evaluated by eGFR, there was no significant difference in various CKD stages in non-IgAN renal function controls (n=42, P=0.352). Alpha 2, 6 SA level of serum IgAl was associated with the prognosis of patients with IgAN and could serve as a predictor of poor prognosis in IgAN. (c) 2007 Elsevier Inc. All rights reserved.